Discussions On Diversity â How To Solve Pharma's Patient Problem By Ed Miseta, Chief Editor, Clinical Leader Follow Me On Twitter @EdClinical Clinical trials need to become more diverse. I think everyone reading this will agree with that statement, although many might disagree on the path to get there. The COVID-19 pandemic has shed a light on inequities that exist in healthcare and clinical trials, which need to be solved before the industry can recruit a more diverse patient population and site network into its studies. PAREXEL has released a report titled Discussions on Diversity, which contains learnings from an extensive series of global surveys, focus group sessions, interviews, and Patient Advisory Council meetings. The report highlights feedback from patients, the general public, and physicians who were willing to engage in candid discussions on the topic of racial and ethnic diversity in clinical trials.